Mirvetuximab soravtansine
- Generic Name
- Mirvetuximab soravtansine
- Brand Names
- Elahere
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1453084-37-1
- Unique Ingredient Identifier
- 98DE7VN88D
- Background
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1.
...
- Indication
Mirvetuximab soravtansine is indicated for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.
...
- Associated Conditions
- Platinum-resistant Epithelial Ovarian Cancer, Platinum Resistant Primary Peritoneal Cancer, Platinum drug resistant Fallopian tube cancer
- Associated Therapies
- -
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033
The global immunomodulators market is projected to grow from $317.06 billion in 2024 to $1,237.66 billion by 2034, driven by their use in treating autoimmune diseases, cancer, preventing infections, and managing organ transplant rejection. Key factors include advancements in precision medicine, regional growth in Asia-Pacific, and recent acquisitions and partnerships in the sector.
Top 10 Breast Cancer Treatment Providers | Provides Best Solutions
Breast cancer treatment market employs various drugs, including chemotherapy, hormone therapies, targeted therapies, and immunotherapy. Market growth is driven by increased incidence, research advancements, early detection awareness, personalized medicine, and new drug classes. The market is projected to reach USD 49.2 billion by 2032, with major companies like Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sun Pharmaceutical, Pfizer, Teva Pharmaceutical, and AbbVie leading in innovation and geographical expansion.
EMA Gives Approval to Biosimilars and Several Cancer Treatments
EMA's CHMP recommended approval for 8 new medicines and extended indications for 12 others, including treatments for cancers, hemophilia, meningococcus, and biosimilars for age-related macular degeneration. Updates to COVID-19 vaccines Spikevax and Comirnaty targeting new variants were also recommended. CHMP extended indications for mpox vaccine Imvanex and others, while refusing authorization for Syfovre. Bruno Sepodes was elected as new CHMP chair, prioritizing medicine quality, safety, and efficacy.
EMA's CHMP recommends Hympavzi for hemophilia, Elahere for cancer
Subscribe to BioWorld™ news services.
EMA Gives Approval to Several Cancer Treatments
EMA's CHMP recommended approval for 8 new medicines and extended indications for 12 drugs, including treatments for cancers, hemophilia, meningococcus, and biosimilars for age-related macular degeneration. CHMP also updated COVID-19 vaccines Spikevax and Comirnaty to target new variants. Bruno Sepodes was elected as the new CHMP chair, prioritizing medicine quality, safety, and efficacy.
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
EMA’s CHMP recommended AbbVie’s ovarian cancer drug Elahere for approval in the EU, based on the MIRASOL study showing a 35% reduction in tumor progression or death. The EC will review this recommendation, with a decision expected later this year.
EMA CHMP recommends AbbVie's mirvetuximab soravtansine for ovarian cancer
EMA's CHMP recommends AbbVie's mirvetuximab soravtansine for FRα-positive, platinum-resistant ovarian cancer. Based on Phase III MIRASOL trial, it targets patients with high FRα levels, previously treated with 1-3 regimens. The European Commission will decide later this year, following FDA's full approval in the US as ELAHERE in March.
Mpox vaccine for adolescents and eight new medicines receive EMA approval
EMA authorizes Bavarian Nordic's mpox vaccine Imvanex for adolescents; WHO supports single-dose use for wider reach. CHMP recommends updated mRNA COVID-19 vaccines and approves 8 new medicines, extends 11 others.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19
The Committee for Human Medicinal Products (CHMP) elected Bruno Sepodes as its new chair, effective 21 September. CHMP recommended marketing authorisations for eight new medicines, including Elahere, Hetronifly, Hympavzi, Penbraya, Theralugand, Afqlir, Opuviz, and Pomalidomide Teva. It also recommended extending indications for 12 existing medicines and confirmed the refusal of Syfovre's marketing authorisation. Applications for Durysta, Tecentriq, and Sialanar were withdrawn. CHMP updated Spikevax and Comirnaty vaccines to target new COVID-19 variants.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath